Who Paid My Doc
Dong-Joon Lee
Surgery of the Hand Los Angeles, CA Medical Doctor
NPI 1578623740 CMS profile 70876
6041 Cadillac Ave, Los Angeles, CA 90034
General payments
$1,054
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Dong-Joon Lee of Los Angeles, CA is reported in the CMS Open Payments database as having received $1,054 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 31st percentile of Surgery of the Hand profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $355 | 7 | |
| 2024 | General | $52 | 1 | |
| 2023 | General | $241 | 2 | |
| 2022 | General | $218 | 2 | |
| 2020 | General | $119 | 1 | |
| 2019 | General | $68 | 2 |
Beside peers
- Dong-Joon Lee
- Surgery of the Hand median
- Middle half of Surgery of the Hand
- National median
In program year 2025, general payments to Dong-Joon Lee were reported at $355. Among 286 Surgery of the Hand profiles paid that year, the median was $288 and the middle half received between $115 and $1,242.
Show as a table
| Year | Dong-Joon Lee | Surgery of the Hand median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $68 | $369 | $108–$1,516 | $163 |
| 2020 | $119 | $153 | $56–$898 | $114 |
| 2021 | $0 | $261 | $84–$1,296 | $132 |
| 2022 | $218 | $313 | $103–$1,562 | $149 |
| 2023 | $241 | $241 | $95–$876 | $160 |
| 2024 | $52 | $236 | $84–$890 | $164 |
| 2025 | $355 | $288 | $115–$1,242 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
102
Drug cost
$1,029
Branded share of claims
46.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 33 | $374 | |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | Brand | 21 | $242 | |
| Ibuprofen | Generic | 22 | $208 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 12 | $106 | |
| Ondansetron Odt Ondansetron | Brand | 14 | $99 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,399 Part D prescribers listed as Hand Surgery; they describe a distribution and say nothing about conduct.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgery of the Hand in California
Related records
Surgery of the Hand in California
Practitioners in the same specialty and state, ranked by reported value.
All Surgery of the Hand
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.